FUNDAMENTALS · Fundamentals · TH Healthcare

Wattana Karnpaet Public (NEW) Fundamentals 2026 — P/E 21.4x, Revenue Analysis | SniperIQ

Wattana Karnpaet Public (NEW) is a TH-listed Healthcare company in Medical - Care Facilities with a market capitalization of ฿870M, trading at ฿87.00 on the SET. This SniperIQ fundamentals page covers Wattana Karnpaet Public's valuation (P/E 21.4x, P/B 1.6x), profitability (net margin 8.9%), revenue (฿453M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap฿870M
P/E (TTM)21.4x
Net Margin8.9%
Revenue (FY25)฿453M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Wattana Karnpaet Public's market cap?

Wattana Karnpaet Public (NEW) has a market capitalization of approximately ฿870M, trading at ฿87.00 on the SET. Market cap moves with the live share price.

What is Wattana Karnpaet Public's P/E ratio?

Wattana Karnpaet Public's trailing twelve-month P/E ratio is 21.4x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Wattana Karnpaet Public?

Wattana Karnpaet Public runs a net profit margin of 8.9%, a gross margin of 22.6%, and an operating margin of 10.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Wattana Karnpaet Public generate?

Wattana Karnpaet Public reported revenue of ฿453M for fiscal year 2025, with net income of ฿39M and earnings per share (EPS) of 3.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Wattana Karnpaet Public pay a dividend?

Wattana Karnpaet Public offers a trailing dividend yield of about 1.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Wattana Karnpaet Public financially healthy?

Wattana Karnpaet Public carries a debt-to-equity ratio of 0.01x and a current ratio of 1.96x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Wattana Karnpaet Public a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Wattana Karnpaet Public (NEW) the key facts are: market cap ฿870M, P/E 21.4x, revenue ฿453M, 52-week range 80.5-142. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Wattana Karnpaet Public's full fundamentals live

Get Wattana Karnpaet Public's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Sana Biotechnology (SANA) fundamentals · Arbutus Biopharma (ABUS) fundamentals · Clarity Pharmaceuticals (CU6) fundamentals · Tian An Medicare (0383) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons